초록

A formulation for reducing corneal scarring and related eye conditions, is disclosed. The formulation comprises an effective amount of fibromodulin and can be administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye.

대표청구항 ▼

1. An eye formulation, comprising: an effective amount of fibromodulin effective for reducing scarring in an injured corneal tissue of a patient, a second agent, and a pharmaceutically acceptable carrier,wherein the formulation is suitable for topical application to an eye of the patient,wherein the

1. An eye formulation, comprising: an effective amount of fibromodulin effective for reducing scarring in an injured corneal tissue of a patient, a second agent, and a pharmaceutically acceptable carrier,wherein the formulation is suitable for topical application to an eye of the patient,wherein the formulation is an aqueous suspension,wherein the effective amount is about 0.0001% to about 5% fibromodulin by weight, andwherein the formulation has a viscosity such that the formulation has a residence time in the eye from about 2 to 12 hrs. 2. The eye formulation of claim 1, which is an eye drop. 3. The eye formulation of claim 1, which provides sustained release of the fibromodulin. 4. The eye formulation of claim 1, wherein the second agent is a therapeutic agent. 5. The eye formulation of claim 1, wherein the second agent is an anti-inflammatory agent, an antibacterial agent, or an analgesic agent. 6. The eye formulation of claim 1, wherein the carrier is an aqueous carrier. 7. The eye formulation of claim 6, wherein the formulation is a liquid suspension having a pH from about 5 to about 8. 8. The eye formulation of claim 1, wherein the corneal tissue has been injured by a damaging condition selected from the group consisting of: trauma infection, corneal ulcers, chemical burns, ocular cicatricial pemphigoid, Stevens-Johnson syndrome, contact lens-induced keratopathy, and surgery. 9. The eye formulation of claim 1, having an osmotic pressure from about 10 milliosmolar (mOsM) to about 400 mOsM. 10. The eye formulation of claim 1, having a viscosity selected from the group consisting of about 10 to about 25 centipoises, about 10 to about 200 centipoises, about 10 to about 400 centipoises, about 5,000 to about 30,000 centipoise, about 5,000 to about 20,000 centipoise, and about 500 to about 100,000 centipoise. 11. A contact lens comprising an eye formulation according to claim 1. 12. A kit, comprising the eye formulation of claim 1 and an applicator for applying the formulation to an eye of a patient. 13. A method for reducing corneal scarring in a patient comprising: intraocularly administering to an injured corneal tissue in the patient an eye formulation of a composition comprising:an effective amount of fibromodulin for reducing scarring in the injured corneal tissue of the patient, hyaluronic acid and a pharmaceutically acceptable carrier,wherein the eye formulation is an aqueous suspension and is suitable for topical application to an eye of the patient,wherein the effective amount comprises about 0.0001% to about 5% fibromodulin by weight, andwherein the formulation has a viscosity such that the formulation has a residence time in the eye from about 2 to 12 hrs. 14. The method of claim 13, wherein the formulation is an eye drop formulation. 15. The method of claim 13, wherein the formulation is a semi-sold topical formulation. 16. The method of claim 13, wherein the formulation is a liquid formulation. 17. The method of claim 13, wherein the formulation is a liquid suspension having a pH from about 5 to about 8. 18. The method of claim 13, wherein the formulation provides a sustained release of the fibromodulin. 19. The method of claim 18, wherein the formulation is included in a contact lens. 20. The method of claim 13, wherein the corneal tissue has been injured by a damaging condition selected from the group consisting of: trauma infection, corneal ulcers, chemical burns, ocular cicatricial pemphigoid, Stevens-Johnson syndrome, contact lens-induced keratopathy, and surgery.